Beneficial effect of Astragalus membranaceus on estimated glomerular filtration rate in patients with progressive chronic kidney disease

详细信息	查看全文 | 推荐本文 |

• 作者：Masumi Okuda^a ; Satoshi Horikoshi^a ; Masakazu Matsumoto^a ; Mitsuo Tanimoto^a ; Hiromichi Yasui^b ; Yasuhiko Tomino^a ; ^{yasu@juntendo.ac.jp}
• 关键词：CKD stages 4 and 5 ; Controlled before-and-after trial ; Herbal medicine ; Progressive kidney disease ; Renoprotective effect
• 刊名：Hong Kong Journal of Nephrology
• 出版年：2012
• 期刊代码：137_15615413
• 类别：med
• 出版时间：April, 2012
• 卷：14
• 期：1
• 页码：17-23
• 文件大小：432 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background/Purpose

Several types of herbal preparations have been used as supplementary therapies for the treatment of progressive chronic kidney disease (CKD), but the scientific evidence for their use is scarce. The aim of the present study was to determine the effects of Astragalus membranaceus on renal outcome in patients with progressive CKD.

Methods and Results

The study population consisted of 35 patients with CKD stages 4 and 5 whose estimated glomerular filtration rate (eGFR) decreased over a 3-month period before the start of A membranaceus treatment despite the use of conventional therapy (from 14.6 卤 6.28 mL/min/1.73 m² to 11.6 卤 5.24; mean 卤 SD, p < 0.05). Similarly, the eGFR of 15 patients with CKD stage 4 decreased over the same period despite conventional therapy (from 20.8 卤 4.59 to 16.7 卤 4.17; r = 鈭?.298; p < 0.05), but increased after the initial period of 3 months of supplementary treatment with A membranaceus (to 18.6 卤 5.67; r = 0.973; p < 0.05) and remained at that level at 6 months (17.8 卤 5.60) and 12 months (16.3 卤 5.89). However, in 20 patients with CKD stage 5, the beneficial effect of A membranaceus was limited to the first 3 months only (鈭? months: 10.5 卤 2.7, baseline: 8.0 卤 2.75, 3 months: 8.4 卤 2.96, 6 months: 6.8 卤 2.45). A membranaceus had no significant effects on other laboratory parameters. Only seven patients (1 in stage 4 and 6 in stage 5) required dialysis within 12 months of A membranaceus treatment, whose eGFR at baseline was relatively low (7.4 卤 1.06).

Conclusion

The results suggest that A membranaceus can maintain stable levels of eGFR and delay the initiation of renal replacement therapy in patients with progressive CKD stage 4.

鑷充粖宸叉湁鏁哥ó鑽夎棩瑁藉姂琚噳鐢ㄦ柤閫茶鎬ф參鎬ц厧鐥?CKD)鐨勮鍏呯檪娉曪紝鐒惰€屾鐢ㄩ€斾粛缂轰箯鐩搁棞鐨勭瀛哥悊鎿氥€傛湰鐮旂┒鏃ㄥ湪鎺㈣◣鑶滆帰榛冭€?Astragalus membranaceus)灏嶉€茶鎬KD鎮ｈ€呯殑鑵庤嚐鏁堟噳銆傜爺绌跺皪璞＄偤35浣嶇4鎴?鏈烠KD鎮ｈ€咃紝鍗充娇鍦ㄥ父瑕忔不鐧備笅(涓嶅寘鎷?em>A membranaceus)锛屽叾鑵庣挡鐞冮亷婵剧巼浼扮畻鍊?eGFR)浠嶅湪3鍊嬫湀鍏ф槑椤笅闄?寰?4.6 卤 6.28 mL/min/1.73 m²鑷?1.6 卤 5.24; mean 卤 SD, p < 0.05)銆傚叾涓?5浜虹偤绗?鏈烠KD鎮ｈ€咃紝eGFR鏂艰┎娈垫湡闁撴槑椤笅闄?寰?0.8 卤 4.59鑷?6.7 卤 4.17; r = 鈭?.298; p < 0.05)锛屼絾鍦ㄨ啘鑾㈤粌鑰嗚鍏呯檪娉曢枊濮嬪緦3鍊嬫湀鍥炲崌(鑷?8.6 卤 5.67; r = 0.973; p < 0.05)锛屼甫缍寔绌╁畾鏂?鍊嬫湀(17.8 卤 5.60)鍙?2鍊嬫湀(16.3 卤 5.89)銆傚彟澶?0浣嶇偤绗?鏈烠KD鎮ｈ€咃紝鑶滆帰榛冭€嗗皪鍏舵晥鐩婂儏鍙鏂奸3鍊嬫湀(鈭?鍊嬫湀: 10.5 卤 2.7, 鍩虹窔: 8.0 卤 2.75, 3鍊嬫湀: 8.4 卤 2.96, 6鍊嬫湀: 6.8 卤 2.45)銆傝嚦鏂煎叾浠栧椹楀闋呯洰锛岃啘鑾㈤粌鑰嗕甫涓嶅叿鏄庨’鏁堟噳銆傚湪鑶滆帰榛冭€嗙殑12鍊嬫湀娌荤檪鏈熼枔锛屽儏7浜?绗?鏈燂細1浜猴紱绗?鏈燂細6浜?闇€鎺ュ彈閫忔瀽娌荤檪锛屽叾鍩虹窔eGFR鍧囧亸浣?7.4 卤 1.06)銆傚洜姝わ紝灏嶆柤绗?鏈熼€茶鎬KD鎮ｈ€咃紝鑶滆帰榛冭€嗘湁鍔╃董鎸乪GFR鏂肩┅瀹氭按骞筹紝涓﹀欢閬茶厧鑷熸浛浠ｇ檪娉曠殑闁嬪鏅傞枔.